Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
15.73
-0.59 (-3.62%)
Sep 12, 2025, 4:00 PM EDT - Market closed
Zymeworks Revenue
Zymeworks had revenue of $48.73M in the quarter ending June 30, 2025, with 153.21% growth. This brings the company's revenue in the last twelve months to $122.87M, up 95.94% year-over-year. In the year 2024, Zymeworks had annual revenue of $76.30M with 0.38% growth.
Revenue (ttm)
$122.87M
Revenue Growth
+95.94%
P/S Ratio
9.65
Revenue / Employee
$429,605
Employees
286
Market Cap
1.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ZYME News
- 12 days ago - Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On - Seeking Alpha
- 12 days ago - Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit - Benzinga
- 13 days ago - Zymeworks halts development of cancer drug after trial setback - Reuters
- 13 days ago - Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager - GlobeNewsWire
- 27 days ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - GlobeNewsWire
- 5 weeks ago - Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire